Evotec
Evotec is a leading drug discovery and development company that combines scientific excellence with AI-driven innovation and proprietary technology platforms to accelerate the journey from concept to cure.
Classification
Profile
Funding
Funding details not yet available.
Accelerates drug discovery and development through scientific excellence, proprietary next-gen technology platforms, and AI-driven innovation.
Pharmaceutical and biotechnology companies seeking to advance medicines from concept to cure.
Services and partnerships for drug discovery and development across various modalities.
Strategic partnerships and direct engagement with industry clients.
Strategic alliances with pharmaceutical and biotech firms to accelerate medicine development.
R&D, technology platform maintenance, and operational costs for drug discovery services.
Proprietary next-gen technology platforms, AI-driven innovation capabilities, and deep disease understanding.
Drug discovery, preclinical development, and integrating breakthrough science with advanced technologies.
Collaborative partnerships focused on accelerating client drug development timelines.
Competes with other drug discovery service providers by leveraging AI and proprietary platforms for precision and speed.
Slow and imprecise drug discovery processes; need for faster, smarter development of life-changing medicines.
- Monetize AI assets as a SaaS offering - Package the target-validation and virtual-screening engines for subscription to smaller biotech f
Are you interested in a deeper dive on the SaaS-AI monetization model (pricing, go-to-market, required tech upgrades)? · Would you like a scenario analysis of expanding GMP capacity in Asia (CAPEX, ROI, regulatory hurdles)? · Do you need a risk matrix focusing on cyber-security (noted 2023 incident) and its impact on the cost structure?
Proprietary technology resources enable the AI-driven value proposition, which directly supports the strategic partnership channels and revenue model.
- Financial validation: 2023 consolidated revenue of €781.4 M (+4% YoY) demonstrates market traction and the ability to fund large-scale R&
Team details not yet available.
No investors recorded yet.